Jessica has been consulting with pharmaceutical companies since 2015. Her two primary focuses are, (1) consulting related to gene and cell therapies and the rare diseases they treat, and (2) leading technical projects that involve claims databases, data analytics, research, and model building.
Jessica has also been involved in the creation and development of Milliman DNA (Demand Insight Accelerator), a product that provides synthesized clinical and scientific research for approved and pipeline gene and cell therapies and estimates the costs and cases associated with these therapies. The product’s intended users are primary insurers, secondary insurers, and pharmaceutical manufacturers.
Jessica has been the lead on many types of technical and non-technical projects, including:
- Assessing the payer landscape and alternate payment models for gene and cell therapies
- Participating in market research with insurers related to gene and cell therapy market access
- Analyzing clinical treatment regimens and pathways before and after diagnosis using claims databases
- Evaluating patient cost sharing and utilization behavior using claims databases
- Creating user-friendly budget impact modeling tools
Prior to consulting with pharmaceutical manufacturers, Jessica was involved with supporting Accountable Care Organizations (ACOs) and provider payment reform, including:
- Performing shared savings agreement financial assessments
- Evaluating physician efficiency using episodes of care
- Evaluating hospital, skilled nursing facility, and home health provider performance
Jessica has led and participated in a variety of research efforts. She has authored white papers and reports, some of which were published by the Society of Actuaries or their affiliated magazine. She has also presented at multiple SOA conferences and has been a guest on the SOA’s Research Insights podcast.
